257 related articles for article (PubMed ID: 35961699)
1. Novel insights into molecular and immune subtypes of biliary tract cancers.
Bramel ER; Sia D
Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
[TBL] [Abstract][Full Text] [Related]
2. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.
Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X
BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
5. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
[TBL] [Abstract][Full Text] [Related]
6. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
8. Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts' position paper.
Fassan M; Angerilli V; Normanno N; Pruneri G; Marchetti A; Grillo F; Tonini G; Scarpa A; Rimassa L
Crit Rev Oncol Hematol; 2024 Feb; 194():104224. PubMed ID: 38211900
[TBL] [Abstract][Full Text] [Related]
9. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
10. The epidemiological trends of biliary tract cancers in the United States of America.
Jiang Y; Jiang L; Li F; Li Q; Yuan S; Huang S; Fu Y; Yan X; Chen J; Li H; Li S; Liu J
BMC Gastroenterol; 2022 Dec; 22(1):546. PubMed ID: 36581813
[TBL] [Abstract][Full Text] [Related]
11. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
12. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
13. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
15. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
Merters J; Lamarca A
J Hepatol; 2023 Mar; 78(3):652-657. PubMed ID: 36400328
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Biliary Tract Cancers: Where Are We?
Kalyan A; Khosla H; Kim RD
Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
[TBL] [Abstract][Full Text] [Related]
17. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
[TBL] [Abstract][Full Text] [Related]
18. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
[TBL] [Abstract][Full Text] [Related]
19. Genomics driven precision oncology in advanced biliary tract cancer improves survival.
Kumar-Sinha C; Vats P; Tran N; Robinson DR; Gunchick V; Wu YM; Cao X; Ning Y; Wang R; Rabban E; Bell J; Shankar S; Mannan R; Zhang Y; Zalupski MM; Chinnaiyan AM; Sahai V
Neoplasia; 2023 Aug; 42():100910. PubMed ID: 37267699
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]